Lina Manufacturing Limited, the pharmaceutical manufacturing arm of Sunshine Holdings PLC, unveiled its new brand identity – a powerful logo that reflects the company’s evolution, vision, and ...

SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global ...

Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on March 27 and set a price target of €16.50. The company’s shares closed yesterday at ...

BERLIN, March 28, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment ...

The Hanover Insurance Group Trading Up 0.4 % Shares of THG opened at $174.56 on Friday. The business’s 50-day moving average price is $163.14 and its 200 day moving average price is $156.91. The ...

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...

The agency inspected the factory after a ProPublica investigation in December found that the plant, operated by Glenmark Pharmaceuticals, was responsible for an outsized share of recalls for pills ...

Purdue Pharma has filed a new bankruptcy plan as part of a $7.4 billion settlement to resolve thousands of lawsuits over the company’s alleged role in the opioid crisis, months after the Supreme ...

Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step toward finalizing a proposed opioid settlement of at least $7.4 billion after a setback in the U.S. Supreme Court last year.

Purdue Pharma submitted a new bankruptcy plan Tuesday, which will give its creditors more than $7.4 billion in cash—including up to $7 billion in payments from the billionaire Sackler family ...

American medical giants have written to the Trump administration, urging it to consider Australia's Pharmaceutical Benefits Scheme as an "unfair trade practice" and to impose "reciprocal" tariffs.